University of the Pacific

Scholarly Commons
School of Pharmacy Faculty Articles

Thomas J. Long School of Pharmacy

12-1-2021

Catatonia: Clinical overview of the diagnosis, treatment, and
clinical challenges
Amber N. Edinoff
Louisiana State University

Sarah E. Kaufman
Louisiana State University

Janice W. Hollier
Louisiana State University

Celina G. Virgen
University of Arizona

Christian A. Karam
Louisiana State University

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.pacific.edu/phs-facarticles
Part of the Medicine and Health Sciences Commons

Recommended Citation
Edinoff, A. N., Kaufman, S. E., Hollier, J. W., Virgen, C. G., Karam, C. A., Malone, G. W., Cornett, E. M., Kaye,
A. M., & Kaye, A. D. (2021). Catatonia: Clinical overview of the diagnosis, treatment, and clinical
challenges. Neurology International, 13(4), 570–586. DOI: 10.3390/neurolint13040057
https://scholarlycommons.pacific.edu/phs-facarticles/598

This Article is brought to you for free and open access by the Thomas J. Long School of Pharmacy at Scholarly
Commons. It has been accepted for inclusion in School of Pharmacy Faculty Articles by an authorized
administrator of Scholarly Commons. For more information, please contact mgibney@pacific.edu.

Authors
Amber N. Edinoff, Sarah E. Kaufman, Janice W. Hollier, Celina G. Virgen, Christian A. Karam, Garett W.
Malone, Elyse M. Cornett, Adam M. Kaye, and Alan D. Kaye

This article is available at Scholarly Commons: https://scholarlycommons.pacific.edu/phs-facarticles/598

Review

Catatonia: Clinical Overview of the Diagnosis, Treatment,
and Clinical Challenges
Amber N. Edinoff 1, *, Sarah E. Kaufman 1 , Janice W. Hollier 1 , Celina G. Virgen 2 , Christian A. Karam 3 ,
Garett W. Malone 3 , Elyse M. Cornett 4 , Adam M. Kaye 5 and Alan D. Kaye 4
1

2

3

4

5

*



Citation: Edinoff, A.N.; Kaufman,
S.E.; Hollier, J.W.; Virgen, C.G.;
Karam, C.A.; Malone, G.W.;
Cornett, E.M.; Kaye, A.M.; Kaye, A.D.
Catatonia: Clinical Overview of the
Diagnosis, Treatment, and Clinical
Challenges. Neurol. Int. 2021, 13,
570–586. https://doi.org/10.3390/
neurolint13040057
Academic Editor: Motohiro Okada
Received: 25 October 2021
Accepted: 26 October 2021
Published: 8 November 2021

Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in

Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Shreveport,
1501 Kings Hwy, Shreveport, LA 71103, USA; sarah.kaufman@lsuhs.edu (S.E.K.);
janice.hollier@lsuhs.edu (J.W.H.)
Department of Anesthesiology, College of Medicine-Phoenix, University of Arizona, Phoenix, AZ 84006, USA;
celinav@email.arizona.edu
School of Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA;
cjk002@lsuhs.edu (C.A.K.); gwm002@lsuhs.edu (G.W.M.)
Department of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA;
elyse.bradley@lsuhs.edu (E.M.C.); alan.kaye@lsuhs.edu (A.D.K.)
Department of Pharmacy Practice, Thomas J. Long School of Pharmacy, University of the Pacific,
Stockton, CA 95211, USA; akaye@pacific.edu
Correspondence: amber.edinoff@lsuhs.edu

Abstract: Catatonia is a syndrome that has been associated with several mental illness disorders
but that has also presented as a result of other medical conditions. Schizophrenia and other psychiatric disorders such as mania and depression are known to be associated with catatonia; however,
several case reports have been published of certain medical conditions inducing catatonia, including
hyponatremia, cerebral venous sinus thrombosis, and liver transplantation. Neuroleptic Malignant
Syndrome and anti-NMDA receptor encephalitis are also prominent causes of catatonia. Patients
taking benzodiazepines or clozapine are also at risk of developing catatonia following the withdrawal
of these medications—it is speculated that the prolonged use of these medications increases gammaaminobutyric acid (GABA) activity and that discontinuation may increase excitatory neurotransmission, leading to catatonia. The treatment of catatonia often involves the use of benzodiazepines,
such as lorazepam, that can be used in combination therapy with antipsychotics. Definitive treatment
may be found with electroconvulsive therapy (ECT). Aberrant neuronal activity in different motor
pathways, defective neurotransmitter regulation, and impaired oligodendrocyte function have all
been proposed as the pathophysiology behind catatonia. There are many clinical challenges that
come with catatonia and, as early treatment is associated with better outcomes, it becomes imperative
to understand these challenges. The purpose of this manuscript is to provide an overview of these
challenges and to look at clinical studies regarding the pathophysiology, diagnosis, and treatment of
as well as the complications and risk factors associated with catatonia.
Keywords: schizophrenia; catatonia; benzodiazepines; ECT
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Catatonia is a syndrome that has been associated with several mental illness disorders
but that has also presented with other medical conditions. It is defined as a group of
symptoms that involve a lack of movement as well as a lack of communication. It can
be accompanied by agitation, confusion, and restlessness. It is a complex psychomotor
syndrome that was previously seen as a subtype of schizophrenia; however, with changes
to the DSM-5, it can now be classified as stemming from other mental health disorders,
including brief psychotic, schizophreniform, and schizoaffective disorders, as well as
having been induced by a substance [1]. It is most commonly associated with bipolar
disorder. It may also be diagnosed independently of any syndromes or medical illness [2].
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Catatonia was first categorized by Karl Kahlbaum as its own entity in 1874 [3].
Emil Kraepelin’s description of catatonia differed from Kahlbaum’s in that he attempted to
tie catatonia into his vision of dementia praecox [3]. This is the collection of symptoms that
characterized early definitions of schizophrenia. Eugen Bleuler brought Kraepelin’s idea
that catatonia equated schizophrenia to the United States and even indicated this his textbook, which was written in 1916 [3]. Bleuler took it a bit further and thought that a patient
with catatonia was suppressing unpleasant memories by “silence, tenseness and rigidity,
refusal to obey commands, and displacing rising emotion and tensions into motor acts that
shut out reality” [3]. Although it was often previously categorized with schizophrenia or
associated with other mental health disorders and neurological disorders, new changes
in the DSM-5 have opened up an opportunity for it to be recognized independently of
these conditions. This is a huge step forward, as catatonia is not just associated with
psychiatric disorders.
Catatonia has a complex presentation that is composed of multiple signs and symptoms, of which only three need to be present for diagnosis. It may be thought of as occurring
with schizophrenia or with mania; however, patients in other settings with various general
medical health conditions may develop an episode of catatonia. It is essential to identify catatonia early on for treatment to protect the patient from developing any further
complications. A number of medical conditions can mask catatonia, delaying its treatment.
Some general medical conditions may also present with catatonic symptoms or place
patients at a higher risk of catatonia, and several case reports have been published on the
subject. These case reports include conditions such as hyponatremia, cerebral venous sinus
thrombosis, and liver transplantation, among others [4–6]. Patients taking benzodiazepines
or clozapine are also at risk of developing catatonia after withdrawal from these medications [7]. It is speculated that the prolonged use of these medications increases GABA
activity and that discontinuation may increase excitatory neurotransmission, leading to
catatonia [7]. Despite this reaction, benzodiazepines are still used as the main form of
treatment for catatonia.
The diagnostic criteria for catatonia in the current DSM-5 require three or more of the
following symptoms: stupor, waxy flexibility, catalepsy, mutism, posturing, negativism,
stereotypes, mannerisms, grimacing, agitation, echopraxia, and echolalia [8]. These diagnostic criteria apply to both adults and children, but in children, catatonia often presents
as a result of somatic conditions or substance use. Catatonia associated with schizophrenia in children is considered serious and needs immediate attention, as there is a greater
opportunity for poor prognosis [8]. Patients who develop catatonia accompanied with
acute autonomic instability have an increased risk of complications and mortality [9,10].
This autonomic instability can be suggestive of a cause that needs immediate treatment.
The treatment of catatonia often involves the use of benzodiazepines, such as lorazepam,
that can be used in combination therapy with antipsychotics to minimize symptoms [11].
Definitive treatment may be found with electroconvulsive therapy (ECT), which provides
patients with short electrical brain stimulation under anesthesia. ECT has been proven to
be effective in the treatment of catatonia, especially with early initiation [11].
Given the various presentations and symptoms for catatonia, it can be challenging
to diagnose and to treat it if not identified correctly and in a timely manner. Catatonia
may be underdiagnosed in populations with mental illness or general medical conditions.
Although the changes made in the DSM-5 aim to address the under-recognition of this
condition and the discrepancies previously noted in the DSM-4, its presentation may
still be missed. It is essential for healthcare professionals to consider it as part of the
differential diagnosis in those presenting with criteria that meet the diagnosis of catatonia.
This manuscript will look at the different causes and the management of catatonia.
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2. Catatonia Causes, Presentation, and Pathophysiology
2.1. Types of Catatonia
There are three types of catatonia that clinicians need to be aware of. The first, and
most common, is akinetic catatonia. A patient with this type of catatonia will stare and
appears to be non-responsive [12]. Response to vocal and noxious stimuli is decreased [9].
These patients are alert and aware of their surroundings. The second type of catatonia is
excited catatonia. A patient with this type may move, but their movements seem pointless
and impulsive. They can appear agitated, combative, or even delirious [12]. The excess
motor activity could cause either harm to the patient themself or harm to others [9]. The last
type is malignant catatonia. This type of catatonia is dangerous and is associated with
autonomic instability [12]. This can be seen in neuroleptic malignant syndrome and can
signal a potential lethal underlying cause of the catatonia. Malignant catatonia can evolve
rapidly, within a matter of days [13]. It is because of this rapid evolution that clinicians
need to keep this in mind when seeing a person with suspected catatonia and act quickly
to treat the underlying cause.
Although not an official subtype of catatonia, periodic catatonia can present as a
diagnostic challenge for clinicians and should be discussed. Periodic catatonia is a rare
form of catatonia where the symptoms present in phases and can disappear completely in
between episodes [14]. The pathophysiology of periodic catatonia is unclear at this time,
though it may be related to a dysfunctional GABA signal since acute cases respond well to
benzodiazepines [15]. There have been cases reported where treatment with an atypical
antipsychotic relieved symptoms [15].
2.2. Causes
It is important to note that catatonia is a constellation of symptoms that are a result of an underlying disorder. Catatonia itself is not a disorder but rather a syndrome.
Psychiatric disorders are the first source that comes to mind when thinking about the
underlaying causes of catatonia. Patients with bipolar disorder, autism, schizophrenia,
major depressive disorder, or mixed psychiatric conditions all have a higher incidence
of catatonia than the general population [16]. In fact, roughly 35% of individuals with
schizophrenia will show symptoms of catatonia at some point [17]. It is because of this that
it is important to keep catatonia in mind in patients with schizophrenia when abnormal
movement and communication is present, as this could be a presentation of neuroleptic
malignant syndrome, a life-threatening syndrome that can be caused by antipsychotic use.
Roughly 20% of patients with catatonia have a medical cause rather than a psychiatric
one [18]. Additionally, general medical conditions such as strokes, neoplasms, infections,
autoimmune disorders, neurodegenerative diseases, metabolic derangements, and certain
drugs have all been associated with catatonia [18]. Infectious and autoimmune etiologies
account for roughly 29% of cases associated with general medical causes, and studies have
shown that meningitis and encephalitis as well as systemic bacterial, viral, or fungal
infections may result in catatonia [19]. Further, autoimmune processes, particularly
N-methyl-D-aspartate receptor (NMDAR) encephalitis and systemic lupus erythematous
(SLE) also have a strong association with catatonia [19]. In fact, NMDAR encephalitis is
responsible for 72% of all autoimmune cases of catatonia. The percentages presented in this
section are meant to highlight that catatonia should be on the clinician’s radar whenever
the syndrome is even slightly suspected. The exact reason why some medical conditions
lead to catatonia is not well understood; however, direct neurotoxic effects, the patient’s
psychological reaction to the insult, or mediation by acute phase reactants have all been
suggested as potential causes [19,20].
Another interesting theory of the cause of catatonia seen in the literature is catatonia
that happens in the face of extreme fear. There is a theory that catatonia is originally derived
from encounters with predators whose attack instincts were based on movements [21].
The thought is that catatonia could be an end state response to the feelings of imminent
doom [21]. A study in an elderly population found that catatonic patients experienced
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more anxiety and hyperactivity [22]. This also may lend credibility to the notion that
anxiety and fear can be part of the causes of catatonia, although catatonia is more complex
and has more probable causes.
2.3. Pathophysiology
The pathophysiology of catatonia is not currently well understood. However, recent
studies suggest that three motor pathways within the brain and brainstem are responsible [23–25]. The first pathway leads from the primary motor cortex (M1) to the putamen,
the internal and external pallidum, the thalamus, and then back to M1. This pathway is
responsible for the inhibition and excitation of movements [24,25]. Another circuit runs
between the M1, thalamus, cerebellum, and pontine nuclei and is responsible for motor
dynamics and timing [23–25]. Lastly, the third circuit is composed of the M1, supplementary motor area (SMA), posterior parietal cortex, and medial prefrontal cortex and controls
motor organization and speed [23–25]. The dysfunction of any of these circuits could lead
to catatonic symptoms. Blood flow to the M1 and SMA has been shown to be increased
in patients with catatonia compared to those without catatonia, further suggesting the
increased neural activity of these circuits, likely resulting in catatonic behavior [26–29].
Reduced GABA activity, specifically GABA-A receptor activity, in the right lateral
orbitofrontal and right posterior parietal cortex is thought to be another driver of the
dysfunction seen in catatonia syndrome [30]. This dysfunction could explain the motor
and affective symptoms seen in catatonia. This would explain why patients with catatonia respond well to and why benzodiazepines remain the mainstay of treatment for
catatonia. This class of drugs stimulates GABA-A binding and relieves the symptoms of
catatonia, presumably by lowering the increased neural activity in the circuits described
above. Dysfunctional connections between the orbitofrontal cortex and the medial prefrontal cortices can be partially reversed by the administration of benzodiazepines, and
imaging shows reduced GABA-A receptor density in cortical areas such as the left sensorimotor cortex [31,32]. Therefore, dysfunctional GABA-A signaling also seems to contribute
to catatonia.
Not only are GABA-A receptors associated with catatonia, but the excitatory glutamatergic N-methyl-D-aspartate receptor (NMDAR) appear to be associated as well.
Glutamate abnormalities have been seen in the basal ganglia [33]. Glutamate hyperactivity is thought to be the cause of catatonia symptoms in this case. As previously stated,
NMDAR encephalitis is strongly associated with catatonia, even more so than it is with
psychosis [19]. During this inflammatory process, NMDARs are internalized into cells, and
overall levels of this receptor are decreased [34,35]. Therefore, the dysfunction of both the
NMDAR and GABA-A receptors has been implicated in the pathogenesis of catatonia [33].
Dopamine dysfunction has also long been postulated as a cause for catatonia symptoms. There is some evidence that the potency of a dopamine D2 receptor blockage is
directly related to the risk of exacerbating catatonia or even provoking malignant features [36]. This can be seen in neuroleptic malignant syndrome, which can manifest as
catatonia. A strong dopamine blockade is thought to cause the symptoms seen in this
syndrome. However, another thought is that there is a balance of GABA-A and dopamine
that must be maintained in the mesostriatal and mesocortiolimbic systems as well as in the
hypothalamus. When this system is dysfunctional, the vulnerability to catatonia emerges
from the use of dopamine antagonists [37]. This particular theory of the pathophysiology of catatonia as well as GABA and glutamate dysfunction does not fully explain the
presentation seen in patients.
Other autoimmune disorders can present with catatonia. T-cell mediated disorder, such as acute demyelinating encephalomyelitis, can also present with catatonia [19].
Catatonia is also associated with autoimmune encephalopathies that are associated with
antineuronal antibodies. These antibodies become internalized and cause the neuron to
cease to function [19]. These disorders suggest that the immune system can play an impor-
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tant role in the pathogenesis of catatonia and need to be considered when a differential
diagnosis is formulated.
Studies have shown that catatonia is substantially heritable and that patients have a
roughly 27% risk of experiencing catatonic symptoms if a first-degree relative has been
affected [38–40]. One gene that is implicated in the heritability of catatonia is CNP, which
codes for cyclic nucleotide phosphodiesterase, an enzyme important for oligodendrocyte function and myelination [41]. In mouse models, knockout of this gene leads to a
catatonic and depressive phenotype in the affected mice [42]. Studies have found that
loss-of-function mutations in this gene are more prevalent in schizophrenic patients with
catatonia compared to schizophrenics without catatonia [43]. Taking all of these pieces
together, we can infer that aberrant neuronal activity in different motor pathways, defective
neurotransmitter regulation, and impaired oligodendrocyte function may all be part of the
pathophysiology of catatonia.
2.4. Presentation
The presentation of catatonia is varied. In general, catatonia can be behavior that is
either increased, decreased, or abnormal compared to baseline, and the DSM-5 does not
provide a separate diagnostic code for catatonia as a distinct psychiatric condition [44].
As per the DSM-5, to diagnose catatonia, three of the following twelve symptoms must
be present: stupor (no psychomotor activity; not actively relating to the environment),
catalepsy (passive induction of a posture held against gravity), waxy flexibility (slight,
even resistance to positioning by the examiner), mutism (no, or very little, verbal response
(excluded if known aphasia)), negativism (opposition or no response to instructions or
external stimuli), posturing (spontaneous and active maintenance of a posture against
gravity), mannerism (odd, circumstantial caricature of normal actions), stereotypy (repetitive, abnormally frequent, non-goal-directed movements), agitation, grimacing, echolalia
(mimicking another’s speech), and echopraxia (mimicking another’s movements) [44–46].
The Bush Francis Catatonia Rating Scale (BFCRS) overlaps with the DSM-5 criteria
and also adds other presentations, including ambitendency (appearance of being stuck
in indecisive or hesitant movement), automatic obedience (mechanical and reproducible
compliance with examiner’s request, even if dangerous), autonomic abnormality (diaphoresis, palpitations, or abnormal temperature, blood pressure, pulse, or respiratory rate),
combativeness (striking out against others with or without potential for injury), gegenhalten (resistance to positioning by examiner that increases proportionally to applied force),
grasp reflex (strong grasp of any object in proximity of the hand or upon touch), impulsivity
(patient suddenly engages in inappropriate behavior without provocation; afterwards,
can give no or only a facile explanation), mitgehen (exaggerated movements in response
to light pressure), perseveration (whole or partial repetition of actions or verbal content
that is not goal directed), rigidity (resistance by way of increased muscle tone), staring,
verbigeration (continuous, directionless repetition of words, phrases, or sentences), and
withdrawal (no eye contact, refusal to take food or drink when offered, or both; turning
away from examiner or social isolation) [47]. The BFCRS has a total of 23 items that are
tallied to give an overall score. The presentation of a patient with catatonia is not fixed and
may vary from interview to interview, and patients are often cachectic and disheveled [48].
Autonomic instability can also be seen in catatonia. This type of catatonia has been
labeled “malignant catatonia.” This can be due to an underlying condition that can be lifethreatening. Liable blood pressures have been seen in benzodiazepine withdrawal, and case
reports have illustrated that catatonia has also been associated with this withdrawal [49].
These symptoms are thought to be due to the disruption of the GABA system as well as
dopamine disturbances. GABA has been associated with the increased firing of dopamine
cells in the ventral tegmental area and increased metabolism in the striatum [49]. The
thought is that the withdrawal of GABA can lower the dopamine and acetylcholine ratio,
which could cause catatonia [49]. This can lead to the death of the patient, so a high index
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of suspension should be kept if autonomic instability is present in the presence of catatonia
for possible withdrawal.
3. Catatonia Current Treatment
The early initiation of treatment in patients presenting with catatonia can reduce
the risk of complications. When patients develop catatonia, their risk of developing
deep venous thrombosis and pulmonary embolism increases substantially and occurs
frequently [50]. This is due to the patient’s immobility. Other complications include
malnutrition, infection, and muscle contractures, as the patient’s mobility is decreased, and
they may refuse oral intake [51–53]. Despite the development of possible complications,
most patients experience a resolution of symptoms with proper management [54]. As stated
in previous sections, autonomic instability may unmask an underlying condition that is also
causing the catatonia. The treatment of that condition is critical, as autonomic instability
may be part of a life-threatening condition.
The first-line treatment for catatonia is generally benzodiazepines, unless malignant
catatonia is present. Benzodiazepines work on the GABA-A receptors and help to relieve
the GABA dysfunction seen in some patients presenting with catatonia syndrome. Various
benzodiazepines have been studied, and while lorazepam is typically used, others can also
be considered, especially when additional symptoms or disorders are present. Caution
must be used in patients exhibiting delirium, as their presentation can worsen; such patients
may require lower doses for treatment [55]. When catatonia is suspected, a lorazepam
challenge can be performed. This is done by giving a dose of lorazepam, either through
IM or IV, and watching for a response. A response indicates the need for high suspicion
of catatonia. In the case of substance-induced catatonia, a combination of lorazepam
and diazepam has been shown to be an effective treatment plan, with the resolution of
symptoms occurring within a day [56].
The starting dose of lorazepam is 2 to 6 mg/d and can be increased up to 12 to
16 mg/d [54]. With an appropriate dose, a response is usually seen within 3–7 days;
however, a treatment response can be gradual and slow in some cases [57]. There is
no agreement on how long benzodiazepines should be continued in the treatment of
catatonia. However, they are generally discontinued once the underlying illness that was
thought to cause the catatonic symptoms remits [57]. However, tapering can cause the
catatonia symptoms to return, which necessitates the continuation of benzodiazepines for
an unknown amount of time.
ECT has been used to treat various mental disorders for many years and is an established treatment modality that has been proven to be highly effective for several conditions.
Treatment involves brief electrical brain stimulations under anesthesia. ECT is a first-line
treatment in neuroleptic malignant syndrome, malignant catatonia, and delirious catatonia.
ECT is thought to work by increasing cerebral blood flow to the orbitofrontal and parietal
cortices, which increases GABA activity and GABA receptor expression [38]. It can also be
a definitive treatment when treatment with benzodiazepines has failed. The response rate
of catatonia symptoms when ECT is used is around 80–100% [58] It can take several ECT
treatments to achieve the desired results [59]. It can take at least six sessions for symptom
relief to be seen [38]. The number of total ECT sessions needed cannot be predicted. The
termination of ECT can be considered when a full clinical response is achieved or when
there is further clinical improvement after two consecutive sessions [58].
Predictors of a favorable response to ECT are noted to be young age, the presence of
autonomic dysregulation at baseline, daily ECT during the first week of treatment, longer
duration of motor and EEG seizure activity at the final ECT sessions, and less morbidity
in the year after ECT [58]. Contraindications to ECT include myocardial infarction within
3 months, elevated intracranial pressure, pheochromocytoma, cerebral tumors, and cerebral
aneurysms [60]. Associated side effects may include impaired new learning, anterograde
and retrograde amnesia, and autobiographical memory; these side effects usually resolve
within weeks to months, but it may take up to 6 months for cognitive function to return
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to baseline [61–63]. A previous history of cognitive impairment places patients at higher
risk of developing side effects [61]. If patients experience recurrent episodes, ECT may be
continued for maintenance treatment [64].
An emerging form of treatment is Repetitive Transcranial Magnetic Stimulation (rTMS).
Similar to ECT, rTMS provides stimulation to the brain, but it does not require patients
to undergo anesthesia. rTMS does not produce cognitive side effects and can be used in
refractory catatonia for acute or maintenance therapy [65]. This treatment modality can be
considered as an option for patients with catatonic schizophrenia but may be restrictive for
some patients, as it requires daily appointments for several weeks [65]. Addressing the
patient’s co-morbidities and other medical conditions along with catatonia is important in
order to provide optimal treatment.
A second-line treatment if benzodiazepine fails and if ECT is either ineffective or
refused are medications that modulate glutamatergic activity. These are memantine or
amantadine and can be given in twice-daily doses [38]. They are generally well tolerated
and can be used either alone or with a benzodiazepine [38]. A final option is the use
of an atypical antipsychotic. These should be used with caution, as they can actually
worsen catatonia or cause a conversion to malignant catatonia. Atypical antipsychotics
should be used in combination with a benzodiazepine, and a low potency agent should be
used [38]. In cases such as these, aripiprazole should be considered due to its partial agonist
activity [38]. Clozapine is another option that is available for patients with schizophrenia
with catatonia [66].
4. Clinical Challenges
While ECT has been proven to produce a positive response in patients with catatonia, there are challenging aspects aside from the possible side effects resulting from this
treatment modality. One such difficulty is obtaining consent from the patient. Patients in
a catatonic state may be unable to provide full consent or refuse such treatment. In the
USA, the guardian in these cases may make medical decisions; however, ECT treatment
is typically not included, and a petition must be obtained [67]. A catatonic patient’s autonomy sets ethical challenges, as they are unable to fully comprehend the details of ECT
treatment [67,68]. This same challenge presents in adolescent patients; however, healthcare
professionals must consider the risks versus the benefits [68]. ECT has been found to
be safe and effective in the pediatric population and is available as a form of treatment
for them.
Other challenging aspects of catatonia involve its various forms of presentation, one of
them being periodic catatonia. Periodic catatonia is a subtype of catatonia in which patients
regularly experience multiple episodes. Although rare, it is a difficult subtype to diagnose
and treat, as it may disappear before it can be treated [14]. Tang et al. describe a case
of a 73-year-old woman with episodes of appearing ill for 45 years, which was initially
thought to be a non-specific psychosis. She was initially placed on antipsychotics but
was noted to have a good response to benzodiazepines. It was later discovered that her
symptoms and presentation were consistent with periodic catatonia, and she was treated
with multiple sessions of ECT. Her catatonia remained in remission for one year [69].
In patients presenting with multiple episodes of psychosis with symptoms meeting the
criteria for catatonia, periodic catatonia should be considered in the differential diagnosis.
Treating patients with antipsychotics in such cases may exacerbate catatonia and may
induce neuroleptic malignant syndrome or malignant catatonia [70,71]. When neuroleptic
malignant syndrome or malignant catatonia occurs, benzodiazepines have been proven to
be an effective form of treatment for both conditions [71].
5. Clinical Studies
Clinical studies were gathered from PubMed for analysis in this paper. The terms
catatonia with the filters for clinical studies and randomized controlled trial were applied
to the search. The resulting studies are discussed below and are summarized in Table 1.
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Table 1. Clinical studies on diagnosis and treatment of Catatonia.
Author (Year)

Summary

Results

Conclusions

Benarous, Xavier et al.
(2016)

A total of 138 psychiatric
patients between the ages of 4
and 18 were used to evaluate
measures of efficacy of the
PCRS, including sensitivity,
specificity, and ROC. A total of
88 patients met BFCRS criteria
for catatonia,
and 50 controls participated.

The PCRS exhibited a specificity of
1 and a sensitivity ≥0.95 in
diagnosing patients with catatonia.
The AUC for the ROC curve for
patients treated with and without
antipsychotics was ≥0.978.

PCRS was found to be a
valid measure of catatonia
in an adolescent/pediatric
population.

Berardi, D. et al. (1998)

A total of 12 patients with a
history of NMS and 24 controls
were treated with neuroleptics
and were monitored each day
for the presence of
extrapyramidal symptoms
and pathological
psychological symptoms.

Psychological symptoms such as
disorganization (p < 0.002),
confusion (p < 0.0006), and
catatonia (p < 0.01) were identified
as potential risk factors for NMS.
Aspects of neuroleptic dose were
also identified as potential
risk factors.

Catatonia could increase
one’s likelihood of
developing NMS.

Conca, A. et al. (2003)

A total of 59 patients with
catatonic symptoms
were administered
zuclopenthixol-acetate and were
monitored using laboratory
values including serum ferritin,
iron, transferrin concentrations,
body temperature,
and other measures.

A total of 43 of the 59 patients
developed a BTHR that lasted for
≥3 days on average. A total of
39.5% of the patients who
developed a BTHR also developed
ferropenia. A total of 32.2% of all
catatonic patients treated with
zuclopenthisol-acetate experienced
ferropenia but did not develop
signs of NMS.

Ferropenia may be
associated with catatonia
as well as an increased
likelihood of experiencing
a BTHR.

Huang, T. L. et al. (1999)

Families of 34 patients with
catatonic symptoms that were
admitted to Chang Gung
Memorial Hospital at Linkou
between January 1995 and
March 1997 were consulted
regarding the onset of the
patient’s symptoms. Each
patient was monitored and
treated for catatonic symptoms.

The average timespan between the
onset of catatonic symptoms and
emergency department visit varied
significantly among different types
of psychological disorders (with
catatonic symptoms). The majority
of patients with acute catatonic
syndrome had an onset of catatonic
symptoms of <1.83 weeks before
being admitted to the ER. Most
patients with chronic catatonic
syndrome had an onset of catatonic
symptoms of >3.33 weeks before
being admitted to the ER.

Acute or insidious onset of
catatonic symptoms
should be considered
when treating patients
with catatonia.
The difference between
acute or insidious onset
should be considered as
exhibiting catatonic
symptoms for greater than
or less than 2–3 weeks
before receiving treatment.

Kakooza-Mwesige,
Angelina et al. (2015)

A variation of the BFCRS was
used to diagnose 16 patients
between 10 and 24 years of age
with NS. These 16 patients also
met BFCRS criteria for catatonia.
Effects of 0.5 or 1 mg of
lorazepam (dosage determined
by body weight of greater or
less than 30 kg) on symptoms of
NS and catatonia
were monitored.

A total of 6 of the BFCRS scores in
catatonic patients with NS were
reduced by >50% after receiving
treatment with lorazepam. After a
single dose of 0.5 mg of lorazepam,
scores were reduced in 10 of
the 16 patients.

Lorazepam was shown to
successfully treat
symptoms of NS in
patients between the ages
of 10 and 24. This study’s
small-scale findings
indicate that lorazepam
may serve as an effective
treatment for symptoms of
catatonia in patients
with NS.
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Table 1. Cont.
Author (Year)

Summary

Results

Conclusions

Northoff, G. et al. (1995)

A total of 18 patients diagnosed
with acute catatonia received
treatment with 2–4 mg of
lorazepam and were monitored
for dyskinetic motions, serum
HVA concentration, and anxiety
24 h after receiving treatment.

Before treatment, short-term
responsive patients had an average
serum HVA concentration of
130.4 +/− 51.2 pmol/mL while
non-responsive patients had an
average serum HVA concentration
of 73.2 +/− 40.5 pmol/mL. A total
of 24 h after beginning treatment,
short-term responsive patients
received lower SEPS scores
(p = 0.049) but higher AIMS scores
(p = 0.022) and HAM-A scores
(p = 0.025) relative to
nonresponsive patients.

Serum HVA levels,
presence of dyskinetic
motions, and anxiety can
be used to differentiate
between catatonic patients
that do or do not respond
to short-term
lorazepam treatment.

Richter, Andre et al. (2010)

A total of 6 patients diagnosed
with catatonia and 16 healthy
controls were administered
either 1 mg lorazepam or
placebo. fMRI scans were then
performed on each participant
while they were exposed to
appropriate stimuli to trigger
targeted brain activity. Each
catatonic patient was also
examined using the treatment
that was not
initially administered.

Catatonic patients who received
lorazepam rather than placebo were
found to have greater signal
decreases within the ROIs of the
OFC while triggered to experience
negative emotions compared to
healthy controls (p < 0.001).

Decreased GABAergic
activity in the brain may
have a role in the etiology
of catatonia. Abnormal
OFC function is observed
in patients with catatonia.

A total of 12 patients were
observed for catatonic
symptoms over the span of one
year. These catatonic patients
were treated with 1–2 mg
lorazepam when each patient
experienced symptoms of
catatonic syndrome.

A total of 15 cases of catatonic
syndrome were observed in these
12 patients. The three most common
signs of catatonia observed in these
patients were mutism, staring, and
immobility. A total of 66.67% of the
patients in this study who benefited
from lorazepam (1–2 mg) treatment
suffered from CNS symptoms and
not only from psychogenic
catatonia. A total of 80% of the
cases of catatonic syndrome were
resolved in 2 h with lorazepam
administration.

Early diagnosis and
administration of
lorazepam in catatonic
patients may enhance
prognosis and decrease
length of hospitalization.

A total of 21 patients with
mutism and psychomotor
retardation participated in this
3-day study. Patients were
assigned a baseline assessment
using the BPRS on day 1.
Patients were then given 60 mg
of oxazepam or 2 mg of
lorazepam, alternating
treatments between the 2nd and
3rd days. Each patient’s
response to each treatment
was assessed.

Both benzodiazepines were found
to be beneficial in treating
psychomotor retardation
(p < 0.0001). The group that
received oxazepam followed by
lorazepam (10 patients) experienced
greater relief of symptoms relative
to the group of 7 patients who
received lorazepam followed by
oxazepam (p < 0.01).
Each benzodiazepine relieved
symptoms of catatonia in
19/21 patients. The two patients
who did not respond to either
benzodiazepine were later
diagnosed with
Parkinson’s Disease.

This study’s findings
support the findings of
other studies that
lorazepam and oxazepam
may both relieve
symptoms of catatonia via
agonistically binding to
benzodiazepine receptors.

Rosebush, P. I. et al. (1990)

Schmider, J. et al. (1999)
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Ungvari, Gabor S. (2010)

A total of 15 patients diagnosed
with schizophrenia according to
DSM-4 criteria with catatonic
symptoms participated in this
15-week trial. Each patient was
daily given a placebo or 200 mg
amineptine for 6 weeks and
then received the alternate
treatment for 6 weeks,
separated by a 3-week
intermission with no treatment,
and was monitored for
catatonic symptoms.

Amineptine was not found to have
a significant effect on the symptoms
of catatonia in each patient.
No significant differences were
observed between each treatment
group (placebo received first or
amineptine received first), and
neither group showed a significant
reduction in catatonic symptoms
according to each clinical
scale used (p > 0.35).

Dopaminergic pathways
may not contribute
significantly to symptoms
of catatonia in
schizophrenic patients.

Ungvari, Gabor S. et al.
(1999)

A total of 18 patients with
schizophrenia with chronic
catatonic symptoms
participated in this double-blind
crossover trial. Patients received
either placebo or lorazepam
(6 mg daily) for 6 weeks then
alternated treatments for
6 weeks after a wash-out period
lasting 4 weeks. Symptoms of
catatonia were monitored for
each patient at weeks 0, 3, and 6
for each treatment using several
clinical rating scales.

A significant difference was not
observed between lorazepam or
placebo treatment in the reduction
of symptoms of catatonia across all
clinical ratings. No patient
experienced any clinically
significant relief of catatonic
symptoms after receiving either
treatment based on BFCRS criteria.

The source of catatonia in
schizophrenic patients
with chronic catatonic
symptoms may be caused
by different
pathophysiology than in
schizophrenic patients
with acute catatonic
symptoms. Lorazepam
was not found to be an
effective treatment in
schizophrenic patients
with chronic
catatonic symptoms.

Ungvari, Gabor S. et al.
(2005)

A total of 274 patients between
the ages of 18 and 55 years who
had been diagnosed with
chronic schizophrenia for over
5 years were assessed using
numerous clinical rating scales
for the severity of their
psychiatric symptoms including
symptoms of catatonia. These
data were compiled and
analyzed.

An increased BFCRS summed score
for a schizophrenia patient with
catatonia was associated with a
higher SANS summed score
(p < 0.001) and an earlier inception
of catatonic symptoms
(p = 0.002). The catatonic group had
significantly different scores from
the non-catatonic group of patients
on assessments, including the BPRS
(p = 0.0004), SANS (p < 0.001), CGI
(p < 0.001), GAS (p = 0.001), and
NOSIE (+) (p < 0.001).

Symptoms of catatonia
can be distinguished in
patients with chronic
schizophrenia. The
presence of catatonic
symptoms in chronic
schizophrenia patients is
correlated with a worse
prognosis than that of
patients without
catatonic symptoms.

5.1. Pathophysiology
A double-blind, case–control study was performed to observe the effects of lorazepam
on cerebral activity [31]. Patients diagnosed with catatonia were exposed to triggers
targeted to elicit positive or negative emotions while researchers used functional magnetic
resonance imaging (fMRI) to measure areas of elevated activity in the brain [31]. Images
were obtained from catatonic patients after their treatment with 1 mg lorazepam and
placebo, respectively. Images under the same conditions were also performed in healthy
individuals [31]. Regions of interest (ROIs) in the brain associated with Brodmann Areas
were configured, and the intensity of signals in each ROI was measured and compared
between groups [31]. When exposed to triggers that elicited negative emotions, fMRI scans
showed that catatonic patients experienced a greater decrease in neural activity in the
orbitofrontal cortex (OFC) relative to the healthy controls when administered lorazepam
rather than placebo [31]. These findings indicate that patients with catatonia may have
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abnormal function of the OFC and that cerebral GABA signaling may be diminished in
catatonic patients [31].
In a double-blind, placebo-controlled crossover study, patients who experienced
chronic symptoms of catatonia and who were diagnosed with schizophrenia were recruited
to help determine the efficacy of amineptine, a tricyclic antidepressant which also acts
as a mixed serotonin and dopamine reuptake inhibitor and releasing agent, in treating
catatonia in schizophrenic patients [72]. Amineptine has not been officially approved by
the FDA for use in the United States. Each patient was treated for six weeks with either
200 mg amineptine or placebo daily in addition to any medications prescribed before
the study began. They then received the alternative treatment for six weeks following
a wash-out period of 3 weeks [72]. Patients were psychiatrically evaluated using eight
clinical evaluation scales at weeks 0, 6, 9, and 15 [72]. In both patients with catatonic
schizophrenia and in healthy individuals, there was no significant decrease in score relative
to baseline on any of the clinical scales used when amineptine was administered instead of
placebo (p > 0.35) [72]. Disregarding a statistically significant but clinically insignificant
decrease in negative symptoms, amineptine was not found to effectively treat catatonic
symptoms in patients with schizophrenia [72]. These results suggest that the etiology of
catatonia in patients with schizophrenia and catatonic symptoms may not be due to altered
dopaminergic pathways [72].
Another double-blind, placebo-controlled crossover study was performed to evaluate the efficacy of lorazepam in treating chronic catatonic symptoms in clinically stable
schizophrenic patients [73]. Patients were treated daily with 6 mg lorazepam or placebo,
and they were then administered the alternate treatment for six weeks following a washout period of 4 weeks [73]. Each patient was evaluated for psychiatric symptoms using
12 clinical scales, including the BFCRS and the brief psychiatric rating scale (BPRS), at the
beginning of each respective treatment as well as at the third and sixth weeks of each
treatment [73]. A significant difference in average score was not observed between patients
who received lorazepam or placebo on any of the scales that were used (p > 0.05) [73].
There was no clinically significant relief of catatonic symptoms observed in patients who
received lorazepam relative to those who received placebo. Lorazepam has been found to
be an effective treatment in patients suffering from acute catatonia in previous studies but
was shown to be ineffective in treating chronic catatonic symptoms in this study [73–76].
This implies that patients with schizophrenia who suffer from chronic catatonia may have
a different pathophysiology associated with their catatonic symptoms than patients with
schizophrenia and acute catatonia [73].
5.2. Diagnosis
There are data suggesting that catatonia may be underdiagnosed in adolescent and
pediatric populations, which is possibly due to a lack of a universal method for diagnosing
a catatonic episode in young patients [77,78]. In a case–control study, researchers addressed
the lack of a tool to assess catatonia in adolescent and pediatric populations. In this study,
researchers developed the pediatric catatonia rating scale (PCRS) based on established
features of catatonia identified in the BFCRS and previous literature [79]. Differing from
the BFCRS, the PCRS excludes grimacing, agitation, or impulsivity as well as other signs
as components of a catatonic syndrome [79]. However, the PCRS includes six additional
components that the BFCRS lacks, such as word salad and incontinence [79]. The validity
and reliability of the PCRS were analyzed using 138 psychiatric patients [79]. The PCRS was
found to have an Area Under the Curve (AUC) for the Receiver Operating Characteristic
(ROC) of 0.983 with a sensitivity greater than or equal to 0.95 and a specificity of 1 [79]. The
PCRS was thus found to be an efficient screening tool for assessing catatonia in adolescent
and pediatric populations [79].
There has been a difference in time to treatment seen in acute catatonia and chronic
catatonia. An observational study was performed on 34 patients with catatonic symptoms
admitted to one hospital’s emergency department over a 2-year span [80]. Each patient
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was diagnosed by two psychiatrists as having symptoms of catatonia, examined for other
psychiatric symptoms, and then treated accordingly. [80]. Researchers also communicated
with members of each patient’s family to determine the length of time between the onset
of symptoms of catatonia and the time at which each patient was admitted to the emergency department [80]. Patients were assigned to a grouping based on their underlying
symptoms; the four groups included individuals with schizophrenic disorders, neurolepticinduced disorders, mood disorders, and other pre-existing conditions [80]. A significant
difference in the lapse in time between the onset of catatonic symptoms and the date of
admittance to the emergency department was observed between each of the four groups
(p < 0.05) [80]. It was observed that patients who experienced acute catatonic syndrome
endured symptoms for less than 1.83 weeks on average before seeking treatment, while
those who experienced chronic catatonic syndrome endured the associated symptoms for
over 3.33 weeks on average before entering the emergency department [80]. These results
indicate that a distinction of having experienced symptoms for 2–3 weeks before seeking
treatment should be implicated to differentiate between patients experiencing chronic or
acute catatonic symptoms [80].
A prospective one-year study analyzed the symptoms and outcomes of patients
admitted to a psychiatric ward who were diagnosed with catatonia [81]. Throughout one
year, catatonia was diagnosed on 15 occasions across 12 patients [81]. On each occasion,
1–2 mg of lorazepam was administered to the catatonic patient, after which the patient’s
symptoms completely resolved in less than 2 h in 12 cases and partially resolved in
1 case [81]. This study’s findings suggest that for patients with catatonic episodes, the early
identification and administration of lorazepam may be beneficial to the patient’s prognosis
and may shorten the length of the patient’s hospitalization [81].
A trial was conducted to observe whether dopaminergic metabolites, Parkinsonian
motions, and anxiety could be used to predict how a patient with acute catatonia would
respond to short-term lorazepam administration [82]. Patients were treated with 2–4 mg of
lorazepam and were monitored for 24 h [82]. Measurements were taken immediately before
lorazepam administration and 24 h after administration [82]. Metabolic measurements
included serum homovanillic acid (HVA) and serum 3-methoxy-4-hydroxyphenylglycol
(MHPG); Parkinsonian motions were measured according to the Subjective Experiences
of Psychosis Scale (SEPS) and the Abnormal Involuntary Movement Scale (AIMS), and
anxiety was measured using the Hamilton Anxiety Scale (HAM-A) [82]. Before receiving
treatment, patients who responded to short-term lorazepam treatment showed significantly
increased serum HVA (p = 0.004), AIMS scores (p = 0.022), and HAM-A scores (p = 0.025)
and significantly decreased SEPS scores (p = 0.049) relative to patients who were nonresponsive [82]. These findings suggest that serum HVA, SEPS, AIMS, and HAM-A may
be useful in determining whether a patient with acute catatonia is more likely to respond
to short-term lorazepam treatment [82].
A cross-sectional study examined various associations as well as distinguished criteria
between schizophrenia and catatonia [79]. The study included 225 patients meeting DSM-4
criteria for schizophrenia and catatonic symptoms [79]. A total of 72 of the patients met
relatively more specific criteria adapted from the BFCRS for catatonia [79]. Three of the most
common relevant symptoms of those who met the criteria for catatonia included mutism,
grimacing, and portraying mannerisms [79]. It was observed that patients with more
severe catatonia were more likely to exhibit symptoms of catatonia earlier in life and have
relatively increased negative symptoms [79]. This study demonstrated that several scales,
including the BFCRS, SANS, BPRS, Clinical Global Impression (CGI), Global Assessment
Scale (GAS), and Nurses’ Observation Scale for Inpatient Evaluation (NOSIE (+)) can be
used to distinguish non-catatonic from catatonic patients with chronic schizophrenia [79].
These findings indicate that despite similarities in symptoms, catatonia can be identified
in patients independently from schizophrenia and is associated with a worse prognosis
relative to non-catatonic patients with chronic schizophrenia [79].
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5.3. Complications and Risk Factors
A case–control study was performed to identify risk factors associated with the
development of neuroleptic malignant syndrome (NMS) in patients who had catatonia [80].
A total of 12individuals who met criteria for NMS and 24 individuals without NMS
who were also treated with neuroleptics were included and compared in this study [80].
Previously hypothesized risk factors for NMS, such as elevated neuroleptic dose, were
assessed along with novel possible risk factors such as catatonia and disorganization [81].
Each patient was examined by psychiatrists who monitored for the presence of identified
potential risk factors for developing NMS [80]. Several statistically significant risk factors
for NMS were verified in this study; these risk factors included catatonia, disorganization,
and psychomotor agitation [80]. Behavioral risk factors identified in this study, including
catatonia, should be closely monitored clinically in patients receiving neuroleptics to avoid
the development of NMS [80].
5.4. Treatment
An open, cross-sectional study was performed in 16 African individuals ranging from
10 to 24 years of age to observe the therapeutic efficacy of lorazepam in treating catatonic
patients with nodding syndrome (NS), which was described as a neurological syndrome
characterized by episodes of repetitively dropping the head forward [80]. A variation
of the BFCRS was used to evaluate symptoms of catatonia in each patient with NS [80].
Catatonic symptoms with the greatest average scores in these patients included mutism,
grimacing, and stupor [80]. Patients were administered either 0.5 mg lorazepam or 1 mg
lorazepam, depending on whether their body weight was less than or greater than 30 kg,
respectively [80]. A reduction in a modified BFCRS score of greater than 50% was observed
in six patients [80]. A dose of 0.5 to 1 mg lorazepam was found to reduce symptoms
of catatonia in patients with NS in 13 of the 16 study participants [80]. Lorazepam was
found to be an effective treatment for catatonic symptoms in patients with NS in this study.
However, these findings may need to be replicated in larger-scale controlled experiments
to verify their external validity [80].
A double-blind crossover study was performed to compare how oxazepam and lorazepam affect mutism and psychomotor retardation in psychiatric patients [82]. Patients
were assessed for psychiatric symptoms and received a score of at least a 3 on the Bech–
Rafaelsen Melancholia Rating Scale (BRMRS) criteria of the BPRS pertaining to psychomotor retardation on the first day of the study [82]. Patients were then randomly treated on
the second day with either 2 mg lorazepam or 60 mg oxazepam and were treated with the
opposite medication the following day [82]. Patients were assessed throughout each day for
symptoms of psychomotor retardation using the BRMRS criteria of the BPRS as well as the
100 mm Visual Analog Scale (VAS) [82]. After the first day of treatment, 57% of the patients
who received lorazepam first and 60% of the patients who received oxazepam first had
an average improvement of at least 50% in their psychomotor retardation symptoms [82].
This study’s findings show that 3-hydroxybenzodiazepines, including both lorazepam and
oxazepam, can effectively treat symptoms of catatonia. These findings also suggest that
the effects of both lorazepam and oxazepam in the treatment of catatonia are facilitated by
3-hydroxybenzodiazepines binding to benzodiazepine receptors [82]. Table 1 summarizes
the studies discussed in this section.
6. Conclusions
Catatonia is a complex condition with varying presentations and that is associated
with multiple disorders, which can make recognition, diagnosis, and treatment a challenging process for healthcare professionals. Catatonic symptoms are often associated with
various psychological and neurological disorders, including schizophrenia, neuroleptic
malignant syndrome, and nodding syndrome. Patients with any of the symptoms of
catatonia should be further evaluated for a catatonic syndrome secondary to their medical
condition or independently of a psychiatric diagnosis. Although the etiology of catatonia
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is still unknown, diminished GABA signaling and abnormal OFC stimulation have been
implicated in its pathophysiology.
The onset of catatonic symptoms and the presence of certain risk factors, such as
elevated serum HVA, may help to predict whether a patient will respond to lorazepam.
Benzodiazepines, specifically lorazepam, and ECT have been observed to be effective
in treating acute catatonic symptoms associated with various mental disorders in both
pediatric and adult populations. Early treatment of catatonia can reduce the risk of patients
developing complications.
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